|
|
| September 24, 2010: Dr. Robert A. Byrne and Dr. Michelle O'Donoghue discuss the clinical trial LANCELOT ACS: A Prospective, Randomized, Doub |
Dr. Robert A. Byrne and Dr. Michelle O'Donoghue discuss the clinical trial LANCELOT ACS: A
Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of a Reversible PAR-1
Thrombin Receptor Antagonist in Patients with Acute Coronary Syndromes at TCT 2010.
TBA
[ Download video ] |
|
No comments have been submitted
|